FUT1 Antibody
Description
Definition and Target Overview
FUT1 Antibody is a polyclonal antibody targeting the fucosyltransferase 1 (FUT1) protein, a Golgi membrane enzyme critical for synthesizing the H antigen—a precursor for ABO blood group antigens . FUT1 catalyzes the transfer of fucose to galactose residues in glycoproteins and glycolipids, influencing cell adhesion, immune regulation, and cancer progression .
Key Properties
Cancer Progression and Stemness
-
Breast Cancer: FUT1 regulates cancer stem cell (CSC) properties, including tumorigenesis and metastasis. Knockdown reduces proliferation by 40% (p < 0.01) and invasion by 60% (p < 0.001) in MDA-MB-361 cells .
-
Pan-Cancer Analysis: High FUT1 expression correlates with poor prognosis in adrenocortical carcinoma (ACC), bladder cancer (BLCA), and colon adenocarcinoma (COAD), with hazard ratios (HR) up to 3.277 .
-
Mechanism: Modulates glycosylation of integrins (e.g., β1) and LAMP-1/2, enhancing mTOR signaling and autophagic flux .
Immune Dysregulation
-
Ocular Inflammation: FUT1 deficiency in mice increases IFN-γ+ Th1 cells in lymph nodes, exacerbating corneal opacity and neutrophil infiltration .
-
Atopic Dermatitis (AD): Fut1-knockout mice exhibit elevated IL-4, IL-6, and IgE levels under MC903-induced AD, linking H2 antigen loss to inflammation .
Blood Group Phenotypes
-
Bombay/para-Bombay: Nonfunctional FUT1 alleles (e.g., nonsense mutations) disrupt H antigen synthesis, leading to rare blood types .
Diagnostic and Prognostic Biomarker
Therapeutic Implications
-
Drug Sensitivity: High FUT1 expression reduces sensitivity to chemotherapy (e.g., cisplatin) but enhances responses to tyrosine kinase inhibitors (e.g., erlotinib) .
-
Immune Checkpoint Blockade: Correlates with PD-L1 and CTLA-4 expression in BRCA and THCA .
Functional Studies in Cancer Cell Lines
| Cell Line | FUT1 Knockdown Effect | Assay Type |
|---|---|---|
| UMUC3 (BLCA) | 50% reduction in proliferation (p < 0.05); 70% lower invasion | CCK-8, Transwell |
| HCT116 (COAD) | 30% slower wound healing; 65% fewer colonies (p < 0.01) | Colony Formation |
| MDA-MB-361 (BRCA) | 45% inhibition of migration; altered EMT markers | Wound Healing |
Limitations and Future Directions
-
Heterogeneity: Variability in FUT1 expression across cancer subtypes complicates pan-cancer therapeutic strategies .
-
Immune Modulation: Mechanistic links between FUT1 glycosylation and T-cell activation remain unclear .
-
Clinical Translation: Most data are preclinical; human trials validating FUT1 as a biomarker or target are lacking .
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Recombinant FUT1 from Arabidopsis thaliana was successfully crystallized in two distinct crystal forms. PMID: 27380374
- Research findings indicate that fucosyltransferase 1 (AtFUT1) exists as a non-covalent homodimer in solution. PMID: 27580247
